OLMA

#2511
Olema Pharmaceuticals, Inc. - Common Stock
10.2 7 USD
-0.05%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
10.27
10.27
Jahresspanne
7.76
36.26
Tagesänderung
-4.82%
Monatliche Änderung
-10.15%
6 month change
-56.34%
Jahresänderung
+25.40%
Vorheriger Schlusskurs
10.7 9
Open
10.2 7
Tief
10.2 7
Hoch
10.2 7
Volumen
78
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Olema Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Olema Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Olema Pharmaceuticals, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Olema Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Olema Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Olema Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Olema Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Olema Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Olema Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Olema Pharmaceuticals, Inc. quarterly report, Q1 FY2026
10-Q

Olema Pharmaceuticals, Inc. current report, Q2 FY2026

Full document

Olema Pharmaceuticals, Inc. - 8-K Summary

Business Context and Reporting Period

This Form 8-K reports the results of the Annual Meeting of Stockholders held by Olema Pharmaceuticals, Inc. on June 17, 2026. The filing details the voting outcomes for director elections, executive compensation, and the ratification of the independent auditor.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.

Material Changes and Voting Results

Three proposals were submitted to stockholders:

  • Proposal 1 (Election of Directors): All four Class III nominees were elected to serve until the 2029 annual meeting.
    • Sean Bohen, M.D., Ph.D.: 67,474,365 For; 1,165,382 Withheld.
    • Scott Garland: 66,184,382 For; 2,455,365 Withheld.
    • Yi Larson: 50,371,668 For; 18,268,079 Withheld.
    • Andrew Rappaport: 67,276,575 For; 1,363,172 Withheld.
  • Proposal 2 (Advisory Vote on Executive Compensation): Approved by stockholders.
    • For: 67,969,902
    • Against: 653,979
    • Abstain: 15,867
  • Proposal 3 (Ratification of Auditor): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026.
    • For: 75,811,449
    • Against: 271,918
    • Abstain: 52,520

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. For further details on executive compensation and director biographies, investors should refer to the definitive proxy statement filed on April 29, 2026.

Key Facts for Investor Verification

  • Verify the significant number of votes withheld for director nominee Yi Larson (18,268,079) compared to other nominees.
  • Confirm the total number of broker non-votes (7,496,139) which did not count toward the quorum or final tally for Proposals 1 and 2.
  • Review the April 29, 2026 Proxy Statement for the full context of the executive compensation advisory vote.

Nachrichten